Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy...
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
About this item
Full title
Author / Creator
Usmani, S Z , Sexton, R , Ailawadhi, S , Shah, J J , Valent, J , Rosenzweig, M , Lipe, B , Zonder, J A , Fredette, S , Durie, B , Hoering, A , Bartlett, B and Orlowski, R Z
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Alternative Titles
Full title
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4558587
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4558587
Other Identifiers
ISSN
2044-5385
E-ISSN
2044-5385
DOI
10.1038/bcj.2015.62
